and Miryalaguda in Telangana) and for its oncology formulation unit at Duvvada in Visakhapatnam.ThewarninglettersfollowedtheinspectionofthesesitesbytheUSFDAin November2014, January2015,and February2015 respectively. While the Srikakulamunit...